AAAAAA

   
Results: 1-15 |
Results: 15
Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma
Authors: de Weerdt, O van de Donk, NWCJ Veth, G Bloem, AC Hagenbeek, A Lokhorst, HM
Citation: O. De Weerdt et al., Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma, NETH J MED, 59(2), 2001, pp. 50-56
Uveitis masquerade syndromes
Authors: Rothova, A Ooijman, F Kerkhoff, F Van der Lelij, A Lokhorst, HM
Citation: A. Rothova et al., Uveitis masquerade syndromes, OPHTHALMOL, 108(2), 2001, pp. 386-399
Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy
Authors: Eurelings, M Notermans, NC Van de Donk, NWCJ Lokhorst, HM
Citation: M. Eurelings et al., Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy, MUSCLE NERV, 24(10), 2001, pp. 1295-1302
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
Authors: Lokhorst, HM Schattenberg, A Cornelissen, JJ van Oers, MHJ Fibbe, W Russell, I Van der Donk, NWCJ Verdonck, LF
Citation: Hm. Lokhorst et al., Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome, J CL ONCOL, 18(16), 2000, pp. 3031-3037
Three families with polyneuropathy associated with monoclonal gammopathy
Authors: Manschot, SM Notermans, NC van den Berg, LH Verschuuren, JJGM Lokhorst, HM
Citation: Sm. Manschot et al., Three families with polyneuropathy associated with monoclonal gammopathy, ARCH NEUROL, 57(5), 2000, pp. 740-742
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
Authors: Lokhorst, HM Sonneveld, P Cornelissen, JJ Joosten, P Kooy, MV Meinema, J Nieuwenhuis, HK van Oers, MHJ Richel, DJ Segeren, CN Veth, G Verdonck, LF Wijermans, PW
Citation: Hm. Lokhorst et al., Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma, BONE MAR TR, 23(4), 1999, pp. 317-322
Donor leukocyte infusions inducing remissions repeatedly in a patient withrecurrent multiple myeloma after allogeneic bone marrow transplantation
Authors: van der Griend, R Verdonck, LF Petersen, EJ Veenhuizen, P Bloem, AC Lokhorst, HM
Citation: R. Van Der Griend et al., Donor leukocyte infusions inducing remissions repeatedly in a patient withrecurrent multiple myeloma after allogeneic bone marrow transplantation, BONE MAR TR, 23(2), 1999, pp. 195-197
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regionsin myeloma cell lines
Authors: Kuipers, J Vaandrager, JW Weghuis, DO Pearson, PL Scheres, J Lokhorst, HM Clevers, H Bast, BJEG
Citation: J. Kuipers et al., Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regionsin myeloma cell lines, CANC GENET, 109(2), 1999, pp. 99-107
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
Authors: Roovers, DJ van Vliet, M Bloem, AC Lokhorst, HM
Citation: Dj. Roovers et al., Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines, LEUK RES, 23(6), 1999, pp. 539-548
Adoptive T-cell therapy
Authors: Lokhorst, HM Liebowitz, D
Citation: Hm. Lokhorst et D. Liebowitz, Adoptive T-cell therapy, SEM HEMATOL, 36(1), 1999, pp. 26-29
Intensive treatment for multiple myeloma: Where do we stand?
Authors: Lokhorst, HM Sonneveld, P Verdonck, LF
Citation: Hm. Lokhorst et al., Intensive treatment for multiple myeloma: Where do we stand?, BR J HAEM, 106(1), 1999, pp. 18-27
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
Authors: Segeren, CM Sonneveld, P van der Holt, B Baars, JW Biesma, DH Cornellissen, JJ Croockewit, AJ Dekker, AW Fibbe, WE Lowenberg, B Kooy, MV van Oers, MHJ Richel, DJ Schouten, HC Vellenga, E Verhoef, GEG Wijermans, PW Wittebol, S Lokhorst, HM
Citation: Cm. Segeren et al., Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma, BR J HAEM, 105(1), 1999, pp. 127-130
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: Effects on soluble IL6 receptor and soluble gp130
Authors: Van Zaanen, HCT Lokhorst, HM Aarden, LA Rensink, HJAM Warnaar, SO Van Oers, MHJ
Citation: Hct. Van Zaanen et al., Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: Effects on soluble IL6 receptor and soluble gp130, LEUK LYMPH, 31(5-6), 1998, pp. 551-558
Fever as presenting symptom of multiple myeloma
Authors: Pitz, CCM Lokhorst, HM Hoekstra, JBL
Citation: Ccm. Pitz et al., Fever as presenting symptom of multiple myeloma, NETH J MED, 53(6), 1998, pp. 256-259
Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor Tcells
Authors: Verdonck, LF Petersen, EJ Lokhorst, HM Nieuwenhuis, HK Dekker, AW Tilanus, MGJ de Weger, RA
Citation: Lf. Verdonck et al., Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor Tcells, BONE MAR TR, 22(11), 1998, pp. 1057-1063
Risultati: 1-15 |